Endurant Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Endurant Capital Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-25,500	Closed	-$1.45M	–	75
2018 Q1	$1.45M	Buy	+25,500	New	+$1.52M	0.54%	45
2017 Q1	–	Sell	-15,600	Closed	-$819K	–	96
2016 Q4	$819K	Buy	+15,600	New	+$834K	0.34%	55

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Endurant Capital Management's PPH Position: Q2 2018 in Review

Endurant Capital Management sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2018, closing a stake of 25,500 shares — an estimated $1.45M sold.

Endurant Capital Management first reported a position in PPH in Q4 2016 and held it in 2 quarters. The position peaked at $1.45M in Q1 2018. 49 funds tracked by Wall St. Rank hold PPH as of Q2 2018.

Endurant Capital Management reported no remaining VanEck Pharmaceutical ETF position as of Q2 2018 after selling out during the quarter.
Endurant Capital Management sold 25,500 VanEck Pharmaceutical ETF shares in Q2 2018, an estimated $1.45M.
Endurant Capital Management first reported a position in VanEck Pharmaceutical ETF in Q4 2016 and held it in 2 quarters.
Endurant Capital Management's VanEck Pharmaceutical ETF position peaked at $1.45M in Q1 2018.
49 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2018.

Based on Endurant Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.